PMS46 Cost-Utility Analysis of Certolizumab Pegol versus Alternative Tumor Necrosis Factor-Inhibitors, for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.432
https://www.valueinhealthjournal.com/article/S1098-3015(11)01994-2/fulltext
Title :
PMS46 Cost-Utility Analysis of Certolizumab Pegol versus Alternative Tumor Necrosis Factor-Inhibitors, for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01994-2&doi=10.1016/j.jval.2011.08.432
First page :
A310
Section Title :
Muscular-Skeletal Disorders
Open access? :
No
Section Order :
405